Bausch Health Companies Inc. (BHC)
NYSE: BHC · Real-Time Price · USD
7.18
-0.08 (-1.10%)
At close: Sep 15, 2025, 4:00 PM EDT
7.05
-0.13 (-1.81%)
After-hours: Sep 15, 2025, 7:33 PM EDT
Bausch Health Companies Revenue
Bausch Health Companies had revenue of $2.53B in the quarter ending June 30, 2025, with 5.29% growth. This brings the company's revenue in the last twelve months to $9.86B, up 7.13% year-over-year. In the year 2024, Bausch Health Companies had annual revenue of $9.63B with 9.91% growth.
Revenue (ttm)
$9.86B
Revenue Growth
+7.13%
P/S Ratio
0.27
Revenue / Employee
$476,232
Employees
20,700
Market Cap
2.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.63B | 868.00M | 9.91% |
Dec 31, 2023 | 8.76B | 633.00M | 7.79% |
Dec 31, 2022 | 8.12B | -310.00M | -3.68% |
Dec 31, 2021 | 8.43B | 407.00M | 5.07% |
Dec 31, 2020 | 8.03B | -574.00M | -6.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BHC News
- 4 days ago - Bausch Health: Repricing Continues As Deleveraging Gains Traction - Seeking Alpha
- 4 days ago - Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio - Accesswire
- 4 days ago - Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial - Business Wire
- 6 days ago - Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers - Business Wire
- 10 days ago - Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System - Accesswire
- 20 days ago - Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025 - Accesswire
- 25 days ago - Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan - Accesswire
- 4 weeks ago - Bausch + Lomb board members resign after Icahn agreement ends - Reuters